We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lucie and CHOICE Broaden the Growth Runway for Oscar Health
Read MoreHide Full Article
Key Takeaways
Oscar Health extends beyond ACA insurance with Lucie and CHOICE, opening new avenues for revenue growth.
Lucie targets a $650 billion-plus marketplace through commissions & fees without assuming underwriting risk.
CHOICE rides ICHRA adoption as employee lives top 500,000 in 2026, with a target above 2.5 million by 2029.
Oscar Health (OSCR - Free Report) is leveraging its technology-driven insurance model to capitalize on growth opportunities in the U.S. individual health insurance market. While Affordable Care Act (ACA) membership remains its core growth driver, the company is expanding its reach through CHOICE and the Lucie marketplace, creating opportunities for revenue diversification and higher-margin, capital-light growth.
Acquired in 2025, Lucie is an enhanced direct enrollment platform connecting consumers, brokers, employers and insurance carriers. This platform offers opportunities to generate commissions, platform fees and supplemental-product revenues without assuming underwriting risk. Oscar has identified a total marketplace opportunity exceeding $650 billion for Lucie and remains focused on strengthening its capabilities.
Meanwhile, CHOICE provides another growth avenue by capitalizing on the increasing adoption of Individual Coverage Health Reimbursement Arrangements, which enable employers to fund employees' individual health insurance purchases. This trend could support membership expansion, deepen broker relationships and streamline enrollment. At its recent investor day, Oscar highlighted adoption growth from fewer than 0.2 million employee lives in 2023 to more than 0.5 million in 2026, with a target exceeding 2.5 million by 2029.
Together, these initiatives could leverage Oscar's existing technology infrastructure and distribution network to enhance cross-selling, lower customer acquisition costs and improve customer monetization. Lucie's fee-based model could also reduce reliance on underwriting margins, supporting a more diversified earnings mix and expanding Oscar's growth potential beyond traditional insurance operations.
What About Peers?
Molina Healthcare (MOH - Free Report) is well positioned to benefit from several long-term trends supporting government-sponsored healthcare. As of June 30, 2026, total membership of Molina Healthcare decreased 14.3% year over year to around 4.9 million. Rising healthcare utilization, an aging U.S. population and a strategic shift toward D-SNPs should support sustained membership growth for MOH.
Centene Corporation (CNC - Free Report) has shifted its strategy from prioritizing membership growth to improving earnings quality through disciplined pricing and portfolio optimization. Centene continues to benefit from a large and diversified membership base supported by contract wins and expansion in attractive government-sponsored programs. Centene is also shifting toward higher-quality membership, including growing PDP and dual-eligible Medicare exposure.
OSCR’s Price Performance
Shares of Oscar Health have gained 116.1% year to date, outperforming the industry.
Image Source: Zacks Investment Research
OSCR’s Expensive Valuation
The stock is overvalued compared with its industry. It is currently trading at a price-to-earnings multiple of 14.17, higher than the industry average of 9.02.
Image Source: Zacks Investment Research
Estimates for OSCR
The Zacks Consensus Estimate for OSCR’s third and fourth-quarter 2026 earnings per share (EPS) witnessed no movement in the last 30 days. The same holds true for 2026 and 2027.
Image Source: Zacks Investment Research
The consensus estimates for OSCR’s 2026 and 2027 revenues and earnings indicate year-over-year decreases.
View the Zacks #1 Rank List
Image: Bigstock
Lucie and CHOICE Broaden the Growth Runway for Oscar Health
Key Takeaways
Oscar Health (OSCR - Free Report) is leveraging its technology-driven insurance model to capitalize on growth opportunities in the U.S. individual health insurance market. While Affordable Care Act (ACA) membership remains its core growth driver, the company is expanding its reach through CHOICE and the Lucie marketplace, creating opportunities for revenue diversification and higher-margin, capital-light growth.
Acquired in 2025, Lucie is an enhanced direct enrollment platform connecting consumers, brokers, employers and insurance carriers. This platform offers opportunities to generate commissions, platform fees and supplemental-product revenues without assuming underwriting risk. Oscar has identified a total marketplace opportunity exceeding $650 billion for Lucie and remains focused on strengthening its capabilities.
Meanwhile, CHOICE provides another growth avenue by capitalizing on the increasing adoption of Individual Coverage Health Reimbursement Arrangements, which enable employers to fund employees' individual health insurance purchases. This trend could support membership expansion, deepen broker relationships and streamline enrollment. At its recent investor day, Oscar highlighted adoption growth from fewer than 0.2 million employee lives in 2023 to more than 0.5 million in 2026, with a target exceeding 2.5 million by 2029.
Together, these initiatives could leverage Oscar's existing technology infrastructure and distribution network to enhance cross-selling, lower customer acquisition costs and improve customer monetization. Lucie's fee-based model could also reduce reliance on underwriting margins, supporting a more diversified earnings mix and expanding Oscar's growth potential beyond traditional insurance operations.
What About Peers?
Molina Healthcare (MOH - Free Report) is well positioned to benefit from several long-term trends supporting government-sponsored healthcare. As of June 30, 2026, total membership of Molina Healthcare decreased 14.3% year over year to around 4.9 million. Rising healthcare utilization, an aging U.S. population and a strategic shift toward D-SNPs should support sustained membership growth for MOH.
Centene Corporation (CNC - Free Report) has shifted its strategy from prioritizing membership growth to improving earnings quality through disciplined pricing and portfolio optimization. Centene continues to benefit from a large and diversified membership base supported by contract wins and expansion in attractive government-sponsored programs. Centene is also shifting toward higher-quality membership, including growing PDP and dual-eligible Medicare exposure.
OSCR’s Price Performance
Shares of Oscar Health have gained 116.1% year to date, outperforming the industry.
Image Source: Zacks Investment Research
OSCR’s Expensive Valuation
The stock is overvalued compared with its industry. It is currently trading at a price-to-earnings multiple of 14.17, higher than the industry average of 9.02.
Image Source: Zacks Investment Research
Estimates for OSCR
The Zacks Consensus Estimate for OSCR’s third and fourth-quarter 2026 earnings per share (EPS) witnessed no movement in the last 30 days. The same holds true for 2026 and 2027.
Image Source: Zacks Investment Research
The consensus estimates for OSCR’s 2026 and 2027 revenues and earnings indicate year-over-year decreases.
OSCR stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.